Your session is about to expire
← Back to Search
Labetalol vs Nifedipine for Postpartum Hypertension
Study Summary
This trial will compare the effectiveness of two blood pressure medications in women who have just given birth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with chronic high blood pressure or had high blood pressure during pregnancy.Pregnant patients with very high blood pressure (systolic BP of 160 or higher and/or diastolic BP of 110 or higher) when admitted to the hospital for childbirth.I do not have severe asthma or heart block.You gave birth recently, within the last 6 weeks.
- Group 1: Oral Nifedipine
- Group 2: Intravenous labetalol
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you provide details on any previous research done with Intravenous labetalol?
"Currently, 17 trials are studying Intravenous labetalol and 3 of these clinical studies have progressed to Phase 3. Despite the primary location for research being Breckenridge, Colorado, there is an additional 92 sites hosting investigations on this drug."
Has this experimental research been conducted before?
"Intravenous labetalol has been studied exhaustively since its first trial in 2007, which was sponsored by Encysive Pharmaceuticals. The completion of the initial investigation involving 27 participants prompted Phase 2 drug approval. Currently, 17 active clinical trials are taking place across 66 cities and 6 countries worldwide."
How many individuals are partaking in this research endeavor?
"This research initiative is not currently recruiting participants. Originally posted on the first of January 2022, it was last updated in November 2021. If you're looking for other trails to consider, there are 1000 studies related to hypertension and 17 involving intravenous labetalol that are actively accepting candidates."
For what medical complaints is Intravenous labetalol utilized?
"Intravenous labetalol is a commonly prescribed medication to treat vasospastic angina. It is also useful in treating pheochromocytomas, the effects of high altitude, and premature labour."
To what extent is Intravenous labetalol a health risk to individuals?
"The safety of intravenous labetalol is believed to be high, as the treatment has achieved Phase 4 status and thus been granted approval."
Are there vacancies available for those who wish to join this research?
"Per the clinicaltrials.gov website, this trial is not currently enrolling patients. It was posted on January 1st 2022 and last updated November 18th 2021; however, there are numerous other studies actively recruiting people at this time - 1017 to be exact."
Share this study with friends
Copy Link
Messenger